Dronedarone Hcl
Brand names: Multaq
At a glance
- Medicare prescriptions, 2024
- 223,878
- Medicare drug cost
- $278.1M
- Average cost per prescription
- $1,242
- Clinicians who prescribed it
- 7,785
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF).
From the FDA-approved prescribing information (label dated May 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure, MULTAQ doubles the risk of death. MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure. MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Cardiology 39.5%
- Cardiac Electrophysiology 21.5%
- Nurse Practitioners 11.2%
- Interventional Cardiology 10.6%
- Internal Medicine 6.3%
- Physician Assistants 4.7%
- Family Medicine 4.2%
- Geriatric Medicine 0.7%
- Nuclear Medicine 0.2%
- Pharmacists 0.2%
- General Practice 0.2%
- Hospitalist 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 7% from 2019 to 2024.
Biggest change by state since 2019
- New York +22%
- New Jersey +11%
- Arkansas +9%
- California +3%
- Alabama −2%
- Tennessee (smallest change) −30%
- Missouri (smallest change) −28%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | white oval tablet, 17 mm | 4142 |
Sanofi-Aventis U.S. LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | white oval tablet, 17 mm | 4142 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $7,724 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Sanofi US Services Inc. $7,408
- Sanofi-aventis U.S. LLC $316
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.